The Study
Abstract 4268: The allosteric MAT2A inhibitor IDE397 uniquely exploits metabolic liabilities associated with MTAP deletion to perturb DNA replication and repair
This study is like testing a new toy in a lab with just one type of robot, and seeing how it reacts. It doesn't prove the toy works on real kids or even other robots—it just shows what might happen in a controlled experiment.
Analysis score
Maximum 0 for a computational/algorithm study.
Where the score came from
Some cancer cells are missing a gene called MTAP, which makes them weak in making building blocks for DNA. This drug, IDE397, blocks another enzyme (MAT2A) these weak cells rely on, making them fall apart.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 50 / 100
Quality score
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this means the drug could kill only cancer cells with this specific gene flaw, sparing healthy cells.
- 2The drug stops DNA building blocks from being made and blocks one key enzyme (PRMT5) in cells missing MTAP, but doesn't hurt other important cell functions.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Cancer Research
Year
2025
Authors
D. Garbett, Arjun A. Rao, Marcus M. Fischer, J. Vivian, Khristina Magallanes, Natalie Bresnahan, Pari Lanham, A. Rathore, Austin Li, Rebeca M. Choy, J. C. Schultz, Scott R. Tyler, Angelica M. Gonzalez-Sanchez, Zhipeng Fang, K. Trego, Briana E. Marinoni, Yuchen Bai, P. Teriete, Christian R. Frey, Michael A. White, C. Neilan
Related Content
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.